Suggested remit: To appraise the clinical and cost effectiveness of tafasitamab with lenalidomide followed by tafasitamab monotherapy within its marketing authorisation for treating adults with relapsed or refractory diffuse large B-cell lymphoma.
 
Status In progress
Decision Selected
Process STA 2018
ID number 3795

Provisional Schedule

Expected publication 05 October 2022

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Incyte Corporation (tafasitamab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Lymphoma Action
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal college of Radiologists
Associated guideline groups National Clinical Guideline Centre
Associated public health groups None
Comparator companies Pfizer (rituximab) (confidentiality agreement signed, participating)
  Roche Products (polatuzumab, rituximab) (confidentiality agreement signed, participating)
  Teva UK (dexamethasone) (confidentiality agreement signed, participating)
  Accord Healthcare (bendamustine, bleomycin, etoposide, gemcitabine, mitoxantrone, oxaliplatin, prednisolone) (confidentiality agreement not signed, not participating)
  Advanz Pharma (dexamethasone, prednisolone) (confidentiality agreement not signed, not participating)
  Allergan (dexamethasone, prednisolone) (confidentiality agreement not signed, not participating)
  Aspen (chlorambucil, dexamethasone) (confidentiality agreement not signed, not participating)
  Aspire Pharma (dexamethasone) (confidentiality agreement not signed, not participating)
  Bausch & Lomb (dexamethasone, prednisolone) (confidentiality agreement not signed, not participating)
  Baxter Healthcare (cyclophosphamide, mitoxantrone) (confidentiality agreement not signed, not participating)
  Celgene, a BMS company (lenalidomide) (confidentiality agreement not signed, not participating)
  Cheplapharm Arzneimittel GmbH (etoposide) (confidentiality agreement not signed, not participating)
  Consilient Health (dexamethasone) (confidentiality agreement not signed, not participating)
  Dr Reddy’s Laboratories UK (bendamustine) (confidentiality agreement not signed, not participating)
  Ethypharm (dexamethasone) (confidentiality agreement not signed, not participating)
  Glenmark Pharmaceuticals Europe (dexamethasone) (confidentiality agreement not signed, not participating)
  Hameln Pharma (dexamethasone) (confidentiality agreement not signed, not participating)
  Hospira UK (gemcitabine, mitoxantrone, oxaliplatin, vincristine) (confidentiality agreement not signed, not participating)
  Karo Pharma (prednisolone) (confidentiality agreement not signed, not participating)
  Kent Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)
  Kyowa Kirin (bleomycin) (confidentiality agreement not signed, not participating)
  Logixx Pharma (prednisolone) (confidentiality agreement not signed, not participating)
  Medac GmBH (etoposide, lomustine, oxaliplatin) (confidentiality agreement not signed, not participating)
  Napp Pharmaceuticals (rituximab) (confidentiality agreement not signed, not participating)
  Novartis (dexamethasone) (confidentiality agreement not signed, not participating)
  Panpharma UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Phoenix Labs (prednisolone) (confidentiality agreement not signed, not participating)
  Ranbaxy (gemcitabine, oxaliplatin) (confidentiality agreement not signed, not participating)
  Rayner Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)
  Rosemont (dexamethasone) (confidentiality agreement not signed, not participating)
  RPH Pharmaceuticals (prednisolone) (confidentiality agreement not signed, not participating)
  Sandoz (cyclophosphamide, rituximab) (confidentiality agreement not signed, not participating)
  Sanofi (dexamethasone) (confidentiality agreement not signed, not participating)
  Seacross pharmaceuticals (bendamustine, oxaliplatin) (confidentiality agreement not signed, not participating)
  Servier Laboratories (pixantrone) (confidentiality agreement not signed, not participating)
  Synchrony (dexamethasone) (confidentiality agreement not signed, not participating)
  Thame Laboratories (dexamethasone) (confidentiality agreement not signed, not participating)
  Wockhardt UK (dexamethasone, prednisolone) (confidentiality agreement not signed, not participating)
  Zentiva (bendamustine, prednisolone) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics & Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
02 August 2022 Committee meeting: 2
23 June 2022 - 14 July 2022 Draft guidance: 1
01 June 2022 Committee meeting: 1
21 September 2021 Invitation to participate
05 January 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-September 2021 when we will write to you about how you can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
26 August 2020 - 24 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 December 2017 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual